ArticleOncogene2022
Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations.
Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study.Biomolecules · 2026Article
- Hesperadin sensitizes gastric cancer cells to cisplatin via NOX1-dependent oxidative stress.Biomedical reports · 2026Article
- Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/β-catenin signaling.Nature communications · 2025Article
- The ATF4-glutamine axis: a central node in cancer metabolism, stress adaptation, and therapeutic targeting.Cell death discovery · 2025Review
- Protein kinase R regulates pancreatic ductal adenocarcinoma progression by modulating the cell cycle via GADD45A.Scientific reports · 2025Article
- Rsk2 inhibition induces an aneuploid post-mitotic arrest of cell cycle progression in osteosarcoma cells.Cell death discovery · 2025Article
- Article
- New treatment alternatives for primary and metastatic colorectal cancer by an integrated transcriptome and network analyses.Scientific reports · 2024Article
- Comparative transcriptomic analysis reveals the molecular changes of acute pancreatitis in experimental models.World journal of gastroenterology · 2024Article
- Lithium chloride induces apoptosis by activating endoplasmic reticulum stress in pancreatic cancer.Translational oncology · 2023Article
- Therapeutic targeting of the TPX2/TTK network in colorectal cancer.Cell communication and signaling : CCS · 2023Article
- AURKB Enhances Chromosomal Remodeling of Telomeric Genes and Accelerates Tumorigenesis of Uveal Melanoma.Investigative ophthalmology & visual science · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a fatal disease with poor survival and limited therapeutic strategies. In this study, we identified Hesperadin as a potent anti-cancer compound against PC, from a high-throughput screening of a commercial chemical library associated with cell death. Hesperadin induced potent growth inhibition in PC cell lines and patient-derived tumor organoids in a dose- and time-dependent manner, with IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.